CP
SPRB

Castleview Partners’s Spruce Biosciences SPRB Stock Holding History

Castleview Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-796
Closed -$46.9K – 1008
2024
Q1 		$46.9K Buy
+796
New +$202K 0.03% 359

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Castleview Partners's SPRB Position: Q2 2024 in Review

Castleview Partners sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 796 shares — an estimated $46.9K sold.

Castleview Partners first reported a position in SPRB in Q1 2024 and held it in 1 quarter. The position peaked at $46.9K in Q1 2024. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

  • Castleview Partners reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Castleview Partners sold 796 Spruce Biosciences shares in Q2 2024, an estimated $46.9K.
  • Castleview Partners first reported a position in Spruce Biosciences in Q1 2024 and held it in 1 quarter.
  • Castleview Partners's Spruce Biosciences position peaked at $46.9K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Castleview Partners's 13F filing for Q2 2024, filed 31 Jul 2024.